Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US COVID-19 Vaccination Rollout On Track After Early Bumps, J.P. Morgan Panelists Say

Executive Summary

US vaccination campaign will pick up speed now that access is broadening, leaders from Operation Warp Speed, Pfizer, Moderna, McKesson and CVS Health say at a J.P. Morgan panel discussion.

You may also be interested in...



Gritstone Jumps Into COVID-19 Vaccine Race, Eyeing Mutant Strains

The company is developing a vaccine with both adenoviral and mRNA technology that could potentially overcome resistance mutations on the SARS-CoV-2 spike protein.

BioNTech: 'We Could Produce New COVID Variant Vaccine In Six Weeks'

The speed of the new messenger RNA platforms could once again come to the rescue, but the expectation is that existing vaccines should remain effective against the emerging strain.

Krystal Sees Success With Topical Gene Therapy In Debilitating Rare Skin Disorder

A regulatory filing for Vyjuvek in the US is targeted for the first half of 2022 following the positive results of a Phase III trial, positioning Krystal for its first commercial launch.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143625

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel